Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enobosarm - Veru Healthcare

Drug Profile

Enobosarm - Veru Healthcare

Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024

Latest Information Update: 24 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
  • Developer City of Hope National Medical Center; National Cancer Institute (USA); Oncternal Therapeutics, Inc.
  • Class Antineoplastics; Nitriles; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Stress incontinence

Most Recent Events

  • 12 Aug 2021 Veru Healthcare plans a phase II trial for Breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Q3 2021
  • 12 Aug 2021 Veru plans a phase III ARTEST trial for Breast cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) (PO) in the 2H 2021 (NCT04869943)
  • 04 Jun 2021 Updated efficacy data from a phase II trial in Breast cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top